Bilibili Inc. ('Bilibili” or the 'Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today provided an update on its two-year US$300 ...
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos ” or the “Company ”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today ...
The White House criticized a report questioning whether an application for the unapproved drug was for President Trump.
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
The decision focused specifically on Haitian and Syrian immigrants, but legal experts say it could apply to as many as 1.3 ...
The Army Corps of Engineers is not reducing our commitment to value engineering. To the contrary, it's elevating and modernizing value ...
The Ministry of Agriculture is accelerating its nationwide water pumping program to safeguard irrigation supplies ahead of ...
Oregon’s landmark effort allowing adults older than 21 to access psilocybin has evolved beyond “strictly medical uses” and ...
Guidance on processes companies should implement to comply with US export laws and regulations, including conducting key ...
Monster formulas don't have to stay monstrous.
Music Times, LLC on MSN
Suno's New Artist Grant Program Has a Clause That Never Expires
Suno's new Spark grant program offers funding and mentorship to independent artists, but its perpetual non-disparagement clause has sparked debate over artists' rights and AI music contracts.
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results